Related Experiment Video
Updated: Jan 9, 2026
Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
Current Management Strategies of Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections
Juan P Horcajada1, Maria-Milagro Montero2, Sonia Luque3
1Department of Infectious Diseases, Hospital del Mar, Hospital del Mar Research Institute, Universitat Pompeu Fabra (UPF), Passeig Maritim 25, 08003 Barcelona, Spain; CIBER of Infectious Diseases (CIBERINFEC), Institute of Healh Carlos III, Madrid, Spain.
Abstract:
Difficult-to-treat resistant (DTR) Pseudomonas aeruginosa is an important cause of severe health care-associated infections and is associated with high morbidity and mortality. Its complex resistance mechanisms compromise the efficacy of traditional therapies and make treatment increasingly difficult. Although new active therapeutic options such as ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam and cefiderocol are currently available, lack of randomized control trials, drug access limitations, and emerging resistance have a negative impact on the management of these infections. This review discusses the mechanisms of resistance, molecular epidemiology, clinical management, and current and future therapeutic strategies for DTR P aeruginosa infections.
Insights
Difficult-to-treat resistant Pseudomonas aeruginosa causes severe infections. New therapies exist, but challenges like limited trials and emerging resistance impact treatment strategies for these challenging infections.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Difficult-to-treat resistant (DTR) Pseudomonas aeruginosa is a significant cause of healthcare-associated infections.
- DTR P. aeruginosa infections are linked to high morbidity and mortality.
- Complex resistance mechanisms hinder traditional treatment efficacy.
Purpose of the Study:
- To review resistance mechanisms, epidemiology, and management of DTR P. aeruginosa.
- To discuss current and future therapeutic strategies for DTR P. aeruginosa infections.
Main Methods:
- Literature review of resistance mechanisms.
- Analysis of molecular epidemiology.
- Evaluation of clinical management strategies.
Main Results:
- New therapeutic options like ceftolozane-tazobactam are available.
- Challenges include limited randomized controlled trials and emerging resistance.
- Drug access limitations affect infection management.
Conclusions:
- Effective management of DTR P. aeruginosa requires understanding resistance.
- Current therapeutic strategies face significant challenges.
- Future strategies must address emerging resistance and access limitations.
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:30Development of Antibiotic Resistance
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:28Gene Regulation in Microbial Communities: Quorum Sensing